Literature DB >> 29799645

Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.

Triveena M Ramsis1, Shereen E Abdel Karim1, Niki Vassilaki2, Efseveia Frakolaki2, Ahmed A M Kamal3, Grigoris Zoidis4, Nermin S Ahmed1, Ashraf H Abadi1.   

Abstract

Here we report a series of potent anti-HCV agents bearing a symmetrical benzidine l-prolinamide backbone with different capping groups including alkyl/aryl carbamates of natural and unnatural valine and leucine amino acids. All compounds were investigated for their inhibitory activity in an HCV replicon assay on genotype 1b. The novel compounds share some chemical and clinical attributes of commercially available NS5A inhibitors. Compounds 5 and 6 with unnatural capping residue and ethyl and isobutyl carbamates showed EC50 values in the picomolar range with a low toxicity profile and selectivity indices of several orders of magnitude. These findings enlarge the chemical space from which NS5A inhibitors may be discovered by adopting unnatural amino acids, amino acids other than valine and carbamates other than methyl as the capping groups.
© 2018 Deutsche Pharmazeutische Gesellschaft.

Entities:  

Keywords:  NS5A inhibitors; anti-HCV; bivalent ligands; peptidomimetics

Mesh:

Substances:

Year:  2018        PMID: 29799645     DOI: 10.1002/ardp.201800017

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  2 in total

1.  The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.

Authors:  Wieslaw M Kazmierski; Nagaraju Miriyala; David K Johnson; Sam Baskaran
Journal:  ACS Med Chem Lett       Date:  2021-09-15       Impact factor: 4.345

2.  Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.

Authors:  Mai H A Mousa; Nermin S Ahmed; Kai Schwedtmann; Efseveia Frakolaki; Niki Vassilaki; Grigoris Zoidis; Jan J Weigand; Ashraf H Abadi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.